Contact our responsive and friendly client services team any time.
(03) 9028 2888
clients@freshequities.com
Current price
▾0.002 (2.30%)
Last trade: Invalid date GMT
Market cap
Market closed
Pharmaxis Limited (PXS) is a specialty pharmaceutical company involved in the research, development and commercialisation of therapeutic products for chronic respiratory disorders. PXS has two approved products: Bronchitol for cystic fibrosis and Aridol diagnosis of asthma; and four products in development: PXS-4728, LOX platform technology Orbital, ASM8. Headquartered in Sydney at its Frenchs Forest manufacturing facilities, Pharmaxis also has offices in Europe and the United States. Former Names Pharmaxis Limited PXS (11/11/2003)
2/20 Rodborough Rd, Frenchs Forest NSW 2086, Australia
Filter
Announcement | T+2 Movement | Date |
---|---|---|
Day
3m
1yr
5yr
Current price
-
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Company | Market Cap | ||
---|---|---|---|
Live Chat
(03) 9028 2888
clients@freshequities.com
Level 19, 15 William St
Melbourne VIC 3000
Australia